Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 506-511

  Zhou, B ^a   Qie, M ^a   Wang, Y ^b   Yan, L ^a   Zhang, Z ^a   Liang, A ^a   Wang, T ^a   Wang, X ^a   Song, Y ^a   Zhang, L ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cervical squamous cell carcinoma; NFKB1; Polymorphism; Risk

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA SEQUENCE; ETHNIC DIFFERENCE; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA;

EID: 77949593559     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp507     Document Type: Article

References (40)

1. Waggoner SE. Cervical cancer. Lancet 2003; 361: 2217-2225.
2. Curado MP, Edwards B, Shin HR et al. Cancer incidence in five continents. Volume IX. IARC Sci Publ 2008; 160: 1-837.
3. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999; 400: 29-30.
4. Mehta AM, Jordanova ES, van Wezel T et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 2007; 46: 577-586.
5. Engelmark MT, Ivansson EL, Magnusson JJ et al. Polymorphisms in 9q32 and TSCOT are linked to cervical cancer in affected sib-pairs with high mean age at diagnosis. Hum Genet 2008; 123: 437-443.
6. Su TH, Chang TY, Lee YJ et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007; 28: 1237-1240.
7. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17.
8. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005; 446: 475-482.
9. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999; 18: 6925-6937.
10. Pacifico F, Leonardi A. NF-kappaB in solid tumors. Biochem Pharmacol 2006; 72: 1142-1152.
11. Ondrey FG, Dong G, Sunwoo J et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26: 119-129.
12. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-2632.
13. Van Waes C, Yu M, Nottingham L, Karin M. Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res 2007; 13: 4956-4959.
14. Tian F, Zang WD, Hou WH et al. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim Biophys Sin (Shanghai) 2006; 38: 318-326.
15. Loercher A, Lee TL, Ricker JL et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004; 64: 6511-6523.
16. Nair A, Venkatraman M, Maliekal TT et al. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 2003; 22: 50-58.
17. Prusty BK, Husain SA, Das BC. Constitutive activation of nuclear factor -kB: preferential homodimerization of p50 subunits in cervical carcinoma. Front Biosci 2005; 10: 1510-1519.
18. Ramdass B, Maliekal TT, Lakshmi S et al. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol 2007; 104: 352-361.
19. Karban AS, Okazaki T, Panhuysen CI et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35-45.
20. Rueda B, Nunez C, Lopez-Nevot MA et al. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease. Scand J Gastroenterol 2006; 41: 420-423.
21. Oliver J, Gomez-Garcia M, Paco L et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis 2005; 11: 576-579.
22. Zhou B, Rao L, Li Y et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009; 275: 72-76.
23. Li H, Gao L, Shen Z et al. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 2008; 300: 425-433.
24. Lin SC, Liu CJ, Yeh WI et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2006; 243: 47-54.
25. Zhou B, Rao L, Peng Y et al. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet 2009; 10: 47.
26. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
27. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-208.
28. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22: 1387-1398.
29. Borm ME, van Bodegraven AA, Mulder CJ et al. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005; 32: 401-405.
30. Glas J, Torok HP, Tonenchi L et al. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis 2006; 12: 606-611.
31. Mirza MM, Fisher SA, Onnie C et al. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut 2005; 54: 1205-1206.
32. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A 1994; 91: 28-32.
33. Wang W, Abbruzzese JL, Evans DB et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
34. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000; 19: 1123-1131.
35. Kim DW, Gazourian L, Quadri SA et al. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 2000; 19: 5498-5506.
36. Fox CJ, Hammerman PS, Cinalli RM et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17: 1841-1854.
37. Farina AR, Tacconelli A, Vacca A et al. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 1999; 10: 353-367.
38. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435: 29-34.
39. Loch T, Michalski B, Mazurek U, Graniczka M. [Vascular endothelial growth factor (VEGF) and its role in neoplastic processes]. Postepy Hig Med Dosw 2001; 55: 257-274.
40. Levine L, Lucci JA III, Pazdrak B et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63: 3495-3502.